Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis

Bibliography

• WALPORT MJ: Complement. First of twoparts. N Engl. J. Med. (2001) 344:1058–1066.
   Google Scholar
• •Together with part 2 [2], still the most comprehensive review on the function of complement in health and disease.
   Google Scholar
• WALPORT MJ: Complement. Second of two parts. N Engl. J. Med. (2001) 344:1140–1144.
   Google Scholar
• •See [1].
   Google Scholar
• WALPORT MJ, DAVIES KA, MORLEY BJ, BOTTO M: Complement deficiency and autoimmunity. Ann. NY Acad. Sci. (1997) 815:267–281.
   PubMed Web of Science ®Google Scholar
• WALPORT MJ: Complement and systemic lupus erythematosus. Arthritis Res. (2002) 4\(Suppl. 3):5279–S293.
   Google Scholar
• SAHUL A, LAMBRIS JD: Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. immunopharmaco/ogy (2000) 49:133–148.
   PubMedGoogle Scholar
• TROUW LA, ROOS k DAHA MR: Autoantibodies to complement components. Mol. Immunol. (2001) 38:199–206.
   PubMed Web of Science ®Google Scholar
• AGNELLO V KOFFLER D, EISENBBERG JW, WINCHESTER RJ, KUNDEL HG: Clq precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J. Exp. Med. (1971) 134(3 Suppl.):228s.
   Google Scholar
• ANTES U, HEINZ HP, LOOS M: Evidence for the presence of autoantibodies to the collagen-like portion of Clq in systemic lupus erythematosus. Arthritis Rheum. (1988) 31:457–464.
   PubMed Web of Science ®Google Scholar
• UWATOKO S, AOTSUKA S, OKAWA M et al.: Characterization of Clq-binding IgG complexes in systemic lupus erythematosus. Clin. Immunol Immunopathol (1984) 30:104–116.
   PubMedGoogle Scholar
• UWATOKO S, AOTSUKA S, OKAWA M et al.: Clq solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of Clq in sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol (1987) 69:98–106.
   PubMed Web of Science ®Google Scholar
• UWATOKO S, MANNIK M: Low-molecular weight Clq-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of Clq. J. Clin. Invest. (1988) 82:816–824.
   PubMed Web of Science ®Google Scholar
• SIEGERT CE, DAHA MR, HALMA C, VAN DER VOORT E, BREEDVELD FC: IgG and IgA autoantibodies to Clq in systemic and renal diseases. Clin. Exp. Rheumatol (1992) 10:19–23.
   PubMed Web of Science ®Google Scholar
• KOHRO-KAWATA J, WENER MH, MANNIK M: The effect of high salt concentration on detection of serum immune complexes and autoantibodies to Clq in patients with systemic lupus erythematosus. J. Rheumatol (2002) 29:84–89.
   PubMed Web of Science ®Google Scholar
• WENER MH, UWATOKO S, MANNIK M: Antibodies to the collagen-like region of Clq in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum. (1989) 32:544–551.
   PubMed Web of Science ®Google Scholar
• COOK AD, ROWLEY MJ, WINES BD,MACKAY IR: Antibodies to the collagen-like region of Clq and Type II collagen are independent non-cross-reactive populations in systemic lupus erythematosus and rheumatoid arthritis. J. Autoimmun. (1994) 7:369–378.
   PubMed Web of Science ®Google Scholar
• MARTENSSON U, THIEL S, JENSENIUS JC, SJOHOLM AG: Human autoantibodies against Clq: lack of cross reactivity with the collectins mannan- binding protein, lung surfactant protein A and bovine conglutinin. Scand. j Immunol (1996) 43:314–320.
   PubMed Web of Science ®Google Scholar
• SEELEN MA, TROUW LA, VAN DER HOORN jw et al.: Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin. Exp. Immunol (2003) 134:335–343.
   Google Scholar
• COREMANS IE, DAHA MR, VAN DER VOORT E, SIEGERT CE, BREEDVELD FC: Subclass distribution of IgA and IgG antibodies against Clq in patients with rheumatic diseases. Scand. Immunol (1995) 41:391–397.
   PubMed Web of Science ®Google Scholar
• UWATOKO S, MANNIK M: IgG subclasses of antibodies to the collagen-like region of Clq in patients with systemic lupus erythematosus. Arthritis Rheum. (1989) 32:1601–1603.
   PubMed Web of Science ®Google Scholar
• SIEGERT CE, DAHA MR, SWAAK AJ,VAN DER VOORT EA, BREEDVELD FC: The relationship between serum titres of autoantibodies to Clq and age in the general population and in patients with systemic lupus erythematosus. Clin. Immunol Immunopathol (1993) 67:204–209.
   PubMedGoogle Scholar
• SEELEN MA, TROUW LA, DAHA MR: Diagnostic and prognostic significance of anti-Clq antibodies in systemic lupus erythematosus. Curr. Opin. Niphrol Hypertens. (2003) 12:619–624.
   PubMed Web of Science ®Google Scholar
• NAUTA AJ, TROUW LA, DAHA MR et al.: Direct binding of Clq to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol (2002) 32:1726–1736.
   PubMed Web of Science ®Google Scholar
• NAVRATIL JS, WATKINS SC, WISNIESKI JJ, AHEARN JM: The globular heads of Clq specifically recognize surface blebs of apoptotic vascular endothelial cells. J. Immunol (2001) 166:3231–3239.
   PubMed Web of Science ®Google Scholar
• HORVATH L, CZIRJAK L, FEKETE B et al.: High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol (2001) 19:667–672.
   PubMed Web of Science ®Google Scholar
• SIEGERT CE, DAHA MR, WESTEDT ML, VAN DER VOORT E, BREEDVELD FC: IgG autoantibodies against Clq are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J. Rheumatol (1991) 18:230–234.
   PubMed Web of Science ®Google Scholar
• MARTO N, BERTOLACCINI ML, CALABUIG E, HUGHES GR, KHAMASHTA MA: Anti-Clq antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. (2004) (In Press).
   Google Scholar
• •Comprehensive report on anti-Clq autoantibodies in relation to nephritis in SLE. Provides evidence to actively monitor those patients positive for anti-Clq that have not yet developed nephritis for signs of renal involvement.
   Google Scholar
• MORONI G, TRENDELENBURG M, DEL PAPA N et al.: Anti-Clq antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis. (2001) 37:490–498.
   Google Scholar
• TRENDELENBURG M, MARFURT J, GERBER I, TYNDALL A. SCHIFFERLI JA: Lack of occurrence of severe lupus nephritis among anti-Clq autoantibody-negative patients. Arthritis Rheum. (1999) 42:187–188.
   PubMed Web of Science ®Google Scholar
• •First report to describe in detail that anti-Clq autoantibodies are required, but are not sufficient for the development of severe lupus nephritis.
   Google Scholar
• FREMEAUX-BACCHI V, NOEL LH, SCHIFFERLI JA: No lupus nephritis in the absence of anti-Clq autoantibodies? Niphrol Dial. Transplant. (2002) 17:2041–2043.
   Web of Science ®Google Scholar
• GUNNARSSON I, RONNELID J, HUANG YH et al.: Association between ongoing anti-Clq antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br. J. Rheumatol (1997) 36:32–37.
   PubMedGoogle Scholar
• COREMANS IE, SPRONK PE, BOOTSMA H et al.: Changes in antibodies to Clq predict renal relapses in systemic lupus erythematosus. Am. J. Kidney Dis. (1995) 26:595–601.
   PubMed Web of Science ®Google Scholar
• SIEGERT CE, DAHA MR, TSENG CM, COREMANS IE, VAN ES LA, BREEDVELD FC: Predictive value of IgG autoantibodies against Clq for nephritis in systemic lupus erythematosus. Ann. Rheum. Dis. (1993) 52:851–856.
   PubMed Web of Science ®Google Scholar
• CHEN PC, WANG CR, LIU MF, CHEN FF, LIANG CC: Correlation between the renal Clq deposition and serum anti-Clq antibody: a potential role of anti-Clq antibody in lupus nephritis. Asian Pac. J. Allergy Immunol (2002) 20:223–227.
   PubMed Web of Science ®Google Scholar
• UWATOKO S, GAUTHIER VJ, MANNIK M: Autoantibodies to the collagen-like region of Clq deposit in glomeruli via Clq in immune deposits. Clin. Immunol Immunopathol (1991) 61:268–273.
   PubMedGoogle Scholar
• COREMANS IE, BRUIJN JA, DE HEER E, VAN DER VOORT EAIVI, BREEDVELD FC, DAHA MR: Stabilization of glomerular deposits of Clq by antibodies against Clq in mice. J. Clin. Lab. Immunol (1995) 44:47–61.
   Google Scholar
• TROUW LA, SEELEN MA, DUIJS JM, BENEDIKTSSON H, VAN KOOTEN C, DAHA MR: Glomerular deposition of Clq and anti-Clq antibodies in mice following injection of antimouse Clq antibodies. Clin. Exp. Immunol (2003) 132:32–39.
   PubMed Web of Science ®Google Scholar
• HOGARTH MB, NORS WORTHY PJ, ALLEN PJ et al.: Autoantibodies to the collagenous region of Clq occur in three strains of lupus-prone mice. Clin. Exp. Immunol (1996) 104:241–246.
   PubMed Web of Science ®Google Scholar
• TRINDER PK, MAEURER MJ, SCHORLEMMER HU, LOOS M: Autoreactivity to mouse Clq in a murine model of SLE. Rheumatol Int. (1995) 15:117–120.
   PubMed Web of Science ®Google Scholar
• TROUW LA, SEELEN MA, VISSEREN R et al.: Anti-Clq autoantibodies in murine lupus nephritis. Clin. Exp. Immunol (2004) 135:41–48.
   PubMed Web of Science ®Google Scholar
• TROUW LA, GROENEVELD TW, SEELEN MA et al.: Anti-Clq autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular Clq-containing immunecomplexes. j Clin. Invest. (2004) 114:679–688.
   PubMed Web of Science ®Google Scholar
• •First experimental proof for the renal pathogenicity of anti-Clq autoantibodies.
   Google Scholar
• BERDEN JH: Lupus nephritis. Kidney Int. (1997) 52:538–558.
   PubMed Web of Science ®Google Scholar
• EISER AR, KATZ SM, SWARTZ C: Clinically occult diffuse proliferative lupus nephritis. An age-related phenomenon. Arch. Intern. Med. (1979) 139:1022–1025.
   PubMed Web of Science ®Google Scholar
• KASHGARIAN M: Lupus nephritis: lessons from the path lab. Kidney Int. (1994) 45:928–938.
   PubMed Web of Science ®Google Scholar
• ZABALETA-LANZ M, VARGAS-ARENAS RE, TAPANES F, DABOIN I, ATAHUALPA PINTO PJ, BIANCO NE: Silent nephritis in systemic lupus erythematosus. Lupus (2003) 12:26–30.
   PubMed Web of Science ®Google Scholar
• ARBUCKLE MR, MCCLAIN MT, RUBERTONE MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl. J. Med. (2003) 349:1526–1533.
   PubMed Web of Science ®Google Scholar
• •Provides essential information that several autoantibodies precede the clinical onset of SLE in time.
   Google Scholar
• MOSTOSLAVSKY G, FISCHEL R, YACHIMOVICH N et al: Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur. J. Immunol (2001) 31:1221–1227.
   PubMed Web of Science ®Google Scholar
• TROUW LA, SEELEN MA, DAHA MR: Complement and renal disease. Mol Immunol (2003) 40:125–134.
   PubMed Web of Science ®Google Scholar
• LISZEWSKI MK, POST TW, ATKINSON JP: Membrane cofactor protein (MCP or CD46): newest member of the regulator activation gene cluster. Annu. Rev. Immunol (1999) 9:431–455.
   Google Scholar
• SHINKAI Y, RATHBUN G, LAM KP et al.: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell (1992) 68:855–867.
   PubMed Web of Science ®Google Scholar
• TROUW LA, DUIJS JM, VAN KOOTEN C, DAHA MR: Immune deposition of Clq and anti-Clq antibodies in the kidney is dependent on the presence of glomerular IgG. MoL Immunol (2003) 40:595–602.
   PubMed Web of Science ®Google Scholar
• HIEPE F, PFUELLER B, WOLBART K et al: Clq: a multifunctional ligand for a new immunoadsorption treatment. Ther. Apher. (1999) 3:246–251.
   PubMedGoogle Scholar
• PFUELLER B, WOLBART K, BRUNS A, BURMESTER GR, HIEPE F: Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a Clq column: a pilot study. Arthritis Rheum. (2001) 44:1962–1963.
   PubMed Web of Science ®Google Scholar
• TRINDER PK, MARKER-HERMANN E, LOOS M, MAUERER MJ: Functional definition of a B cell epitope, KGEQGEPGA, on Clq the Fc-binding subunit of the first component of complement. Scand. j Immunol (1999) 50:635–641.
   PubMed Web of Science ®Google Scholar
• KOVACS H, CAMPBELL ID, STRONG P et al.: Evidence that Clq binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Biochemistry (1998) 51:17865–17874.
   Google Scholar
• ROOS k NAUTA AJ, BROERS D et al:Specific inhibition of the classical complement pathway by Clq-binding peptides. J. Immunol (2001) 167:7052–7059.
   PubMed Web of Science ®Google Scholar
• COUSER WG: Complement inhibitors and glomerulonephritis: are we there yet? J. Am. Soc. Nephrol. (2003) 14:815–818.
   PubMed Web of Science ®Google Scholar
• KIRSCHFINK M: Targeting complement in therapy. Immunol. Rev. (2001) 180:177–189.
   PubMed Web of Science ®Google Scholar
• ROOS k RAM WADHOEBE TH, NAUTAAJ, HACK CE, DAHA MR: Therapeutic inhibition of the early phase of complement activation. Immunobiology (2002) 205:595–609.
   PubMed Web of Science ®Google Scholar
• QUIGG RJ: Use of complement inhibitors in tissue injury. Trends MoL Med. (2002) 8:430–436.
   PubMed Web of Science ®Google Scholar
• BAO L, HAAS M, BOACKLE SA et al.: Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J. Immunol (2002) 168:3601–3607.
   PubMed Web of Science ®Google Scholar
• BAO L, HAAS M, KRAUS DM et ell.: Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J. Am. Soc. Nephrol (2003) 14:670–679.
   Google Scholar
• BAO L, ZHOU J, HOLERS VM, QUIGG RJ: Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J. Am. Soc. Nephrol. (2003) 14:2516–2525.
   PubMed Web of Science ®Google Scholar
• MARINO M, RUVO M, DE FALCO S, FASSINA G: Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol (2000) 18:735–739.
   PubMed Web of Science ®Google Scholar
• JORDAN SC: Intravenous gamma-globulintherapy in systemic lupus erythematosus and immune complex disease. Clin. Immunol Immunopathol (1989) 53(2 Pt 2):5164–5169.
   Google Scholar
• RONNELID J, HUANG YH, NORRLANDER T et al.: Short-term kinetics of the humoral anti-Clq response in SLE using the ELISPOT method: fast decline in production in response to steroids. Scand. j Immunol (1994) 40:243–250.
   PubMed Web of Science ®Google Scholar
• GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement regulation in mAb-mediated immunotherapy of cancer. Trends Immunol (2004) 25:158–164.
   PubMed Web of Science ®Google Scholar
• GELDERMAN KA, KUPPEN PJ, OKADA N, FLEUREN GJ, GORTER A: Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res. (2004) 64(12):4366–4372.
   PubMed Web of Science ®Google Scholar
• •Comprehensive study on the use of complement and blocking of complement regulators for in vivo antitumour therapy.
   Google Scholar
• FISHELSON Z, DONIN N, ZELL S, SCHULTZ S, KIRSCHFINK M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRP) in tumors. Mol Immunol (2003) 40:109–123.
   PubMed Web of Science ®Google Scholar
• WISNIESKI JJ, JONES SM: Comparisonof autoantibodies to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J. Immunol (1992) 148:1396–1403.
   PubMed Web of Science ®Google Scholar
• NORS WORTHY P, THEODORIDIS E,BOTTO M et al.: Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to Clq and glomerulonephritis. Arthritis Rheum. (1999) 42:1828–1832.
   Google Scholar
• MONOVA D, MONOV S, ROSENOVA K, ARGIROVA T: Autoantibodies against Clq: view on association between systemic lupus erythematosus disease manifestation and Clq autoantibodies. Ann. Rheum. Dis. (2002) 61:563–564.
   PubMed Web of Science ®Google Scholar
• KOHRO-KAWATA J, WEBER MH, MANNIK M: The effect of high salt concentration on detection of serum immune complexes and autoantibodies to Clq in patients with systemic lupus erythematosus. j Rheumatol (2002) 29:84–89.
   PubMed Web of Science ®Google Scholar
• STRIFE CF, LEAHY AE, WEST CD: Antibody to a cryptic, solid phase Clq antigen in membranoproliferative nephritis. Kidney Int. (1989) 35:836–842.
   PubMed Web of Science ®Google Scholar
• GUNNARSSON I, RONNELID J, LUNDBERG I, JACOBSON SH: Occurrence of anti-Clq antibodies in IgA nephropathy. Nephrol. Dial. Transplant. (1997) 12:2263–2268.
   PubMed Web of Science ®Google Scholar
• COREMANS IE, DAHA MR, VAN DER VOORT E, MUIZERT Y, HALMA C, BREEDVELD FC: Antibodies against Clq in anti-glomerular basement membrane nephritis. Clin. Exp. Immunol (1992) 87:256–260.
   PubMedGoogle Scholar
• PROHASZKA Z, DAHA MR, SUSAL C et al.: Clq autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin. Immunol (1999) 90:247–255.
   PubMed Web of Science ®Google Scholar